|Title||ASC-1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of Myopathy.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Villar-Quiles, RN, Catervi, F, Cabet, E, Juntas-Morales, R, Genetti, CA, Gidaro, T, Koparir, A, Yuksel, A, Coppens, S, Deconinck, N, Pierce-Hoffman, E, Lornage, X, Durigneux, J, Laporte, J, Rendu, J, Romero, NB, Beggs, AH, Servais, L, Cossée, M, Olivé, M, Böhm, J, Duband-Goulet, I, Ferreiro, A|
|Date Published||2020 Feb|
OBJECTIVE: Recently, the ASC-1 complex has been identified as a mechanistic link between amyotrophic lateral sclerosis and spinal muscular atrophy (SMA), and 3 mutations of the ASC-1 gene TRIP4 have been associated with SMA or congenital myopathy. Our goal was to define ASC-1 neuromuscular function and the phenotypical spectrum associated with TRIP4 mutations.
METHODS: Clinical, molecular, histological, and magnetic resonance imaging studies were made in 5 families with 7 novel TRIP4 mutations. Fluorescence activated cell sorting and Western blot were performed in patient-derived fibroblasts and muscles and in Trip4 knocked-down C2C12 cells.
RESULTS: All mutations caused ASC-1 protein depletion. The clinical phenotype was purely myopathic, ranging from lethal neonatal to mild ambulatory adult patients. It included early onset axial and proximal weakness, scoliosis, rigid spine, dysmorphic facies, cutaneous involvement, respiratory failure, and in the older cases, dilated cardiomyopathy. Muscle biopsies showed multiminicores, nemaline rods, cytoplasmic bodies, caps, central nuclei, rimmed fibers, and/or mild endomysial fibrosis. ASC-1 depletion in C2C12 and in patient-derived fibroblasts and muscles caused accelerated proliferation, altered expression of cell cycle proteins, and/or shortening of the G0/G1 cell cycle phase leading to cell size reduction.
INTERPRETATION: Our results expand the phenotypical and molecular spectrum of TRIP4-associated disease to include mild adult forms with or without cardiomyopathy, associate ASC-1 depletion with isolated primary muscle involvement, and establish TRIP4 as a causative gene for several congenital muscle diseases, including nemaline, core, centronuclear, and cytoplasmic-body myopathies. They also identify ASC-1 as a novel cell cycle regulator with a key role in cell proliferation, and underline transcriptional coregulation defects as a novel pathophysiological mechanism. ANN NEUROL 2020;87:217-232.
|Alternate Journal||Ann. Neurol.|
|PubMed Central ID||PMC6980348|
|Grant List||UM1 HG008900 / HG / NHGRI NIH HHS / United States |
Beca de investigación en universidades o centros / / Alfonso Martín Escudero Foundation /
/ / University of Paris /
U54 HD090255 / NH / NIH HHS / United States
/ / National Institute of Health and Medical Research /
PI14/00738 / / Carlos III Institute of Health /
PI14/00738 / / Instituto de Salud Carlos III /
MDA602235 / / Muscular Dystrophy Association /
#20923 / / Association Française contre les Myopathies /
R01 HD075802 / HD / NICHD NIH HHS / United States
UM1 HG008900 / NH / NIH HHS / United States
21267 / / French Association against Myopathies /
U54 HD090255 / HD / NICHD NIH HHS / United States
R01 HD075802 / NH / NIH HHS / United States
R03/75-79 / / League against Cancer /
/ / National Center for Scientific Research /
20923 / / French Association against Myopathies /
/ / European Regional Development Fund /